UBC28 Antibody

What is USP28 and why is it significant in research?

USP28 belongs to the DUBs family and plays a crucial role in counteracting the activities of E3 ligases, making it an important modulator of ubiquitination. USP28 is involved in various physiological processes including cell proliferation, differentiation, apoptosis, DNA damage repair, and stress response . Its significance in research has grown substantially due to its involvement in cancer development and progression. Recent studies have demonstrated that USP28 is highly upregulated in multiple cancer types, including pancreatic, colon, non-small cell lung, and bladder cancers, and its overexpression correlates with poor clinical prognosis . The ability of USP28 to deubiquitinate and stabilize proteins like FOXM1 and c-Myc makes it a critical molecule in cancer biology research.

How do researchers distinguish between USP28 antibody specificity and cross-reactivity?

Researchers must validate USP28 antibody specificity through several complementary approaches:

• Western blotting with positive and negative controls: Using tissues or cell lines known to express high (e.g., pancreatic cancer cells) or low levels of USP28, along with USP28-knockdown samples as negative controls.

• Immunoprecipitation followed by mass spectrometry: This confirms that the antibody pulls down USP28 and can identify any cross-reactive proteins.

• Peptide competition assays: Pre-incubating the antibody with a specific peptide against which it was raised should block positive signals.

• Multiple antibody validation: Using two or more antibodies that recognize different epitopes of USP28 to confirm consistent results.

• Correlation with mRNA expression: Comparing protein detection with RT-PCR results to verify that protein expression patterns match transcript levels .

When choosing an antibody for USP28 detection, researchers should review validation data provided by manufacturers and any published literature citing the specific antibody clone.

What are the optimal protocols for using USP28 antibodies in western blotting?

Table 1: Optimized Western Blotting Protocol for USP28 Detection

For optimal results, researchers should note that pancreatic cancer tissues have shown significantly higher USP28 expression compared to normal pancreatic tissues . When analyzing western blot results, it's crucial to properly select housekeeping proteins as loading controls, as β-actin, β-tubulin, and GAPDH can vary in expression under certain pathological conditions .

How can USP28 antibodies be effectively used in immunohistochemistry (IHC)?

When using USP28 antibodies for IHC, researchers should follow these methodological approaches:

• Tissue preparation: Use 4% paraformaldehyde-fixed, paraffin-embedded tissues sectioned at 4-6 μm thickness.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective for USP28 detection.

• Antibody incubation: Use 1:1000 dilution of USP28 antibody (such as Abcam ab126604) as used in pancreatic cancer studies .

• Signal detection: Employ a sensitive detection system such as HRP-conjugated secondary antibodies with DAB substrate.

• Counterstaining: Counterstain nuclei with hematoxylin for proper tissue visualization.

• Evaluation methodology: Have at least two pathologists evaluate specimens in a blinded manner, as practiced in published studies , to avoid bias in interpretation.

When interpreting IHC results, researchers should recognize that USP28 overexpression has been detected in 66.7% (68/102) of pancreatic cancer tissues in clinical studies . This provides a benchmark for expected positivity rates in similar tissue samples.

How can researchers investigate USP28's role in cancer cell proliferation using antibodies?

To investigate USP28's role in cancer cell proliferation, researchers can employ the following antibody-based experimental approaches:

• Proliferation marker co-staining: Use USP28 antibodies in conjunction with proliferation markers like PCNA, cyclin D1, and CDK4. Studies have shown associations between USP28 and these proliferation markers in pancreatic cancer .

• Cell cycle analysis after USP28 manipulation: Following USP28 overexpression or knockdown, analyze cell cycle distribution using flow cytometry in conjunction with western blotting to correlate USP28 levels with cell cycle progression markers.

• In vivo tumor growth models: Establish xenograft models with USP28-overexpressing or USP28-knockdown cancer cells and monitor tumor growth rates. Subsequent immunohistochemical analysis of tumor tissues using USP28 antibodies can reveal the relationship between USP28 expression and proliferative capacity.

• Mechanistic pathway analysis: Employ co-immunoprecipitation with USP28 antibodies to identify binding partners in proliferation pathways. For example, research has shown that USP28 interacts with FOXM1, a critical mediator of the Wnt/β-catenin signaling pathway in pancreatic cancer .

These approaches can help establish a causal relationship between USP28 expression and cancer cell proliferation, potentially identifying targetable mechanisms for therapeutic intervention.

What methods can be used to study USP28's deubiquitinating activity using antibodies?

Studying USP28's deubiquitinating activity requires specialized techniques where antibodies play crucial roles:

Table 2: Methods for Studying USP28 Deubiquitinating Activity

When investigating USP28's deubiquitinating function, it's essential to remember that USP28 has been shown to deubiquitinate and stabilize FOXM1, which subsequently activates the Wnt/β-catenin signaling pathway in pancreatic cancer . This mechanistic insight provides a model system for studying similar deubiquitinating relationships with other potential substrates.

What are common challenges when using USP28 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with USP28 antibodies:

• High background signal

  • Problem: Non-specific binding producing excessive background noise

  • Solution: Optimize blocking conditions (try 5% BSA instead of milk), increase washing steps, and use appropriate antibody dilutions. Consider using highly cross-adsorbed secondary antibodies.

• Weak or absent signal

  • Problem: Insufficient USP28 protein detection

  • Solution: Verify USP28 expression in your samples via RT-PCR, increase protein loading (40-60 μg), optimize antigen retrieval for IHC/IF, and consider signal amplification systems.

• Multiple bands on western blot

  • Problem: Non-specific binding or detection of USP28 isoforms/degradation products

  • Solution: Use freshly prepared samples with protease inhibitors, optimize SDS-PAGE conditions, and validate with positive controls and USP28 knockdown samples.

• Inconsistent results between experiments

  • Problem: Variable antibody performance across experiments

  • Solution: Standardize experimental conditions, use the same lot of antibody when possible, and include appropriate controls in each experiment.

• Discrepancies between protein and mRNA data

  • Problem: USP28 protein levels do not correlate with mRNA expression

  • Solution: Consider post-transcriptional regulation, verify antibody specificity, and use multiple antibodies targeting different epitopes to confirm results .

How should researchers normalize USP28 expression data when traditional housekeeping proteins show variability?

When traditional housekeeping proteins (β-actin, β-tubulin, GAPDH) show variability, researchers should consider these alternative normalization strategies:

• Multiple housekeeping protein approach: Use a combination of housekeeping proteins to create a composite normalization factor, which provides more stable reference than any single protein.

• Total protein normalization (TPN): Stain membranes with total protein stains (Ponceau S, SYPRO Ruby, stain-free technology) before antibody incubation. This method avoids the variability associated with individual housekeeping proteins .

• Tissue-specific housekeeping proteins: Select reference proteins known to remain stable in your specific tissue or experimental condition, as housekeeping proteins can vary by tissue type and pathological state .

• Absolute quantification: Use purified recombinant USP28 protein standards to create a standard curve for absolute quantification, eliminating the need for reference proteins.

• Statistical normalization: Apply advanced statistical methods to normalize data across multiple samples, especially in large-scale proteomic studies.

This issue is particularly relevant as studies have shown significant variation in housekeeping gene expression in various neuropathological events and other disease states . For instance, spinal cord injury induced more than a 2-fold increase in β-actin expression, while no statistically significant difference was found in β-tubulin expression after injury compared with controls .

How are USP28 antibodies contributing to understanding cancer progression mechanisms?

USP28 antibodies have been instrumental in uncovering several key mechanisms through which USP28 promotes cancer progression:

• Cell cycle regulation: Using USP28 antibodies, researchers have demonstrated that USP28 promotes cancer cell growth by facilitating cell cycle progression and inhibiting apoptosis . USP28 has been shown to interact with cell cycle regulators such as cyclin D1 and CDK4.

• Wnt/β-catenin pathway activation: Immunoprecipitation studies with USP28 antibodies have revealed that USP28 deubiquitinates and stabilizes FOXM1, a critical mediator of Wnt/β-catenin signaling, thereby promoting cancer progression .

• Survival pathway modulation: Antibody-based detection methods have shown that USP28 affects expression of survival proteins such as Survivin and anti-apoptotic factors, influencing cancer cell resistance to programmed cell death .

• Metastasis promotion: Research employing USP28 antibodies has begun to elucidate USP28's role in promoting metastatic processes through regulation of epithelial-mesenchymal transition and invasive behavior.

• Therapeutic resistance mechanisms: USP28 antibody-based studies are investigating how USP28 contributes to resistance against conventional and targeted therapies in various cancers.

The integration of USP28 antibodies with advanced technologies like tandem mass tag (TMT) labeling and LC-MS/MS analysis has allowed researchers to identify novel downstream targets and signaling pathways regulated by USP28 , significantly expanding our understanding of cancer progression mechanisms.

What are emerging antibody-based technologies for studying USP28 in precision medicine?

Several cutting-edge antibody-based technologies are emerging for studying USP28 with potential applications in precision medicine:

• Single-cell proteomics: Combining USP28 antibodies with single-cell analysis techniques to understand heterogeneity in USP28 expression and function within tumors, potentially identifying subpopulations of cells with distinct therapeutic vulnerabilities.

• Multiplexed imaging: Using fluorescently labeled USP28 antibodies in multiplexed imaging platforms to simultaneously visualize USP28 expression alongside other markers in the tumor microenvironment, providing spatial context to USP28 function.

• In situ proximity ligation assays: Detecting protein-protein interactions involving USP28 directly in tissue sections, elucidating context-specific molecular mechanisms.

• Artificial intelligence integration: Coupling USP28 antibody-based imaging with AI and machine learning models to analyze larger pools of samples and identify subtle patterns in USP28 expression and localization that correlate with patient outcomes .

• Antibody-drug conjugates (ADCs): Developing USP28-targeted ADCs for potential therapeutic applications, guided by expression data from diagnostic antibody tests.

These emerging technologies may help translate USP28 research into clinical applications by enabling more precise patient stratification and treatment selection. The development of such technologies is particularly important given that USP28 has been identified as an independent prognostic factor for poor survival in pancreatic cancer patients , suggesting its potential utility as a biomarker for aggressive disease.